SEC Form 4 · accession 0000880771-17-000118
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO · Director
Period of report
Jun 20, 2017
Accepted (ET)
Jun 22, 2017 · 4:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 20, 2017 | M | 30,000 | $3.55 | A | 152,209 | D | |
| Common Stock | Jun 20, 2017 | S | 30,000 | $10.9033 | D | 122,209 | D | |
| Common Stock | Jun 20, 2017 | M | 40,000 | $3.55 | A | 162,209 | D | |
| Common Stock | Jun 20, 2017 | S | 40,000 | $10.9132 | D | 122,209 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2,F3 | $3.55 | Jun 20, 2017 | M | 30,000 | D | — | Mar 5, 2020 | Common Stock | 30,000 | 67,654 | D |
| Non-Qualified Stock Option (right to buy)F2,F3 | $3.55 | Jun 20, 2017 | M | 40,000 | D | — | Mar 5, 2020 | Common Stock | 40,000 | 27,654 | D |
Explanation of responses
- F1The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
- F2Granted under the Issuer's 2005 Equity Incentive Plan.
- F325% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.